Assessment of a revolving drug fund for essential asthma medicines in Benin

Agodokpessi, G.; Aït-Khaled, N; Gninafon, M.; Tawo, Leon; Bekou, Wilfried; Perrin, Christophe; Bissell, Karen; Billo, Nils; Enarson, Donald A.; Chiang, Chen Yuan

doi:10.1186/s40545-015-0033-7

Cited by 6 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rather than presuming unaffordability, the quality pharmacoeconomic analysis should influence plans for broadening the alternatives and tactics offered as necessary medications for respiratory disorders in LMICs. Efforts to adapt and incorporate non-pharmacological therapies into care programs will be necessary and strategies to ease the economical delivery of quality-controlled supplies of these drugs ( 133 ). Improving access begins with the establishment of a health staff that is capable of providing CRD services effectively and compassionately.…”

Section: Strengthening Of Healthcare Programsmentioning

confidence: 99%

RETRACTED: Revamping of Chronic Respiratory Diseases in Low- and Middle-Income Countries

Zeng

Hussain

Syed

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

Low- and middle-income countries (LMICs) endure an asymmetrically high burden of worldwide disease and death caused by chronic respiratory diseases (CRDs), i.e., asthma, emphysema, bronchiectasis, and post-tuberculosis lung disease (PTLD). CRDs are firmly related with indigence, infectious diseases, and other non-communicable diseases (NCDs) and add to complex multi-disease with great impact on the lives and livelihood of those affected. The pertinence of CRDs to health and demographic wellbeing is relied upon to increment in the long time ahead, as expectations of life rise and the contending dangers of right on time youth mortality and irresistible infections level. The WHO has distinguished the counteraction and control of NCDs as an earnest improvement issue and crucial for the sustainable development goals (SDSs) by 2030. In this review, we center on CRDs in LMICs. We examine the early life roots of CRDs, challenges in their avoidance, identification and administration in LMICs, and the pathways to resolve for accomplish valid widespread wellbeing inclusion.

show abstract

Section: Strengthening Of Healthcare Programsmentioning

confidence: 99%

RETRACTED: Revamping of Chronic Respiratory Diseases in Low- and Middle-Income Countries

Zeng

Hussain

Syed

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Quality pharmacoeconomic analysis should inform strategies for expanding the options and strategies promoted as Essential Drugs for respiratory diseases in LMICs, rather than assuming unaffordability. Strategies to facilitate the affordable delivery of qualitycontrolled supplies of these medications will then be needed, 140 and efforts to adapt and integrate non-pharmacological interventions into programs of care will be required. The development of a health workforce which can provide CRD services competently and compassionately is at the core of improving access.…”

Section: Improving Access To Treatmentmentioning

confidence: 99%

Improving lung health in low-income and middle-income countries: from challenges to solutions

et al. 2021

Self Cite

View full text Add to dashboard Cite

Low-and middle-income countries (LMICs) bear a disproportionately high burden of the global morbidity and mortality caused by chronic respiratory diseases (CRDs) including asthma, chronic obstructive pulmonary disease, bronchiectasis and post-tuberculous lung disease. CRDs are strongly associated with poverty, infectious diseases, and other non-communicable diseases, and contribute to complex multi-morbidity, with significant consequences for the lives and livelihoods of those affected.The relevance of CRDs to health and socioeconomic wellbeing is expected to increase over time, as life expectancies rise and the competing risks of early childhood mortality and infectious diseases plateau. As such, the World Health Organization has identified the prevention and control of CRDs as an urgent development issue and essential to the achievement of the Sustainable Development Goals.In this review we focus on CRDs in low-and middle-income settings (LMICs). We discuss the early life origins of CRDs, challenges in prevention, diagnosis and management in LMICs, and pathways to solutions to achieve true Universal Health Coverage.

show abstract

“…They contributed to the improved availability of essential medicines. Procurement and distribution-related barriers were addressed through direct distribution of supplies from partners 50,60,130,164,167 , PBF 62 , RDF programmes 92,121,200 , and utilization of ICT 68,70 in stock management. Similar interventions could be used to address the shortfalls of the EML and strengthen the EDL implementation designs.…”

Section: Discussionmentioning

confidence: 99%

“…The WHO also released a handbook for monitoring the building blocks of health systems structured around the six main building blocks of WHO health systems framework's: service delivery, health workforce, health information systems, access to essential medicines, financing, and leadership and governance 198 In this review, there were notable successes of interventions developed to address barriers to the EML implementation that could be considered useful in the EDL implementation. The RDF 92,121,200 , PBF 183,184 , 119, and P4P 67,182 interventions addressed several barriers to implementing the EML: accessibility for care-related barriers, facility-related barriers, incentive-related barriers, information system-related barriers, accountability-related barriers, and facility financial resource-related barriers. The revolving fund pharmacy (RFP) 201 , accredited drug dispensing outlets (ADDOS) 55 , and auditable pharmaceutical services and transaction system (APTS) 84 interventions also addressed the facility-related barriers.…”

Section: Discussionmentioning

confidence: 99%

Implementing essential diagnostics-learning from essential medicines: A scoping review

Nyanchoka

Mulaku

Nyagol

et al. 2022

Preprint

View full text Add to dashboard Cite

Background The World Health Organization (WHO) model list of Essential In vitro Diagnostic (EDL) introduced in 2018 complements the established Essential Medicines List (EML) and improves its impact on advancing universal health coverage and better health outcomes. We conducted a scoping review of the literature on the implementation of the WHO essential lists in Africa to inform the implementation of the recently introduced EDL. Methods We searched eight electronic databases for studies reporting on the implementation of the WHO EDL and EML in Africa. Two authors independently conducted study selection and data extraction, with disagreements resolved through discussion. We used the Supporting the Use of Research Evidence (SURE) framework to extract themes and synthesized findings using thematic content analysis. We used the Mixed Method Appraisal Tool (MMAT) version 2018 to assess the quality of included studies where applicable. Results We included 172 studies reporting on EDL and EML after screening 3,813 articles titles and abstracts and 1,545 full-text papers. Most (75%, n=129) included studies were purely quantitative in design comprising descriptive cross-sectional designs (60%, n=104), 15% (n=26) were purely qualitative, and 10% (n=17) had mixed-methods approaches. There were no qualitative or randomised experimental studies about the EDL. The main barrier facing the EML and EDL was poorly equipped health facilities - including unavailability or stock-outs of essential in vitro diagnostics and medicines and inadequate infrastructure to enable health service delivery. Financial and non-financial incentives to health facilities and workers were a key enabler to the implementation of the EML however, their impact differed from one context to another. Fifty-six (33%) of the included studies were of high quality. Conclusions The EDL implementation at the national level can learn from health system interventions to improve the availability and supply of essential medicines such as financial and non-financial incentives in different contexts.

show abstract

Assessment of a revolving drug fund for essential asthma medicines in Benin

Cited by 6 publications

References 9 publications

RETRACTED: Revamping of Chronic Respiratory Diseases in Low- and Middle-Income Countries

RETRACTED: Revamping of Chronic Respiratory Diseases in Low- and Middle-Income Countries

Improving lung health in low-income and middle-income countries: from challenges to solutions

Implementing essential diagnostics-learning from essential medicines: A scoping review

Contact Info

Product

Resources

About